NYSE · Healthcare · Medical Devices · USA
Haemonetics Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
Haemonetics is a global medical technology company providing automated plasma collection systems and donor management software for plasma centers, blood collection and processing devices for blood centers, and hospital technologies for vascular closure, cell salvage, and blood management. The company operates through three segments: Plasma, Blood Center, and Hospital, serving plasma collectors, blood centers, and healthcare providers worldwide.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Haemonetics Corp stock.
Overvalued: intrinsic value $74.37 per share, market price $120.92, margin of safety -62.6% (as of 2026-11-17).
Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $74.37; the price of $120.92 is 63% above that value, and 80% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
33 more in this industry show a wider margin of safety.
HAE is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 7.9% (average of 3 methods) values the shares at $74.37; the price of $120.92 is 63% above that value, and 80% of that value comes from beyond year five.
$74.37 per share (as of the 2026-11-17 close), against a market price of $120.92. That is a margin of safety of -62.6%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.